The U.S. FDA has granted de novo clearance for Epiminder Pty. Ltd.’s Minder implantable device for continuously monitoring brain activity in patients with epilepsy.

There is a growing drive for innovative treatments as up to one-third of the estimated 50 million people with epilepsy do not respond to existing therapies. While current therapies include surgery, ...

Budget cuts and staff layoffs affecting federally supported epilepsy research and patient support have advocacy groups ...

Creditors signed a Deed of Company Arrangement with Cadwell Industries, Breakthrough Victoria and Singapore's TrialCap, in a ...

Get Instant Summarized Text (Gist) Common genetic variants in the genes CNIH3 and WDR26 are linked to drug resistance in focal epilepsy, affecting the efficacy of antiseizure medications. This ...

Epilepsy, a seizure disorder that affects about ... Union's Horizon Europe research and innovation program. The implanted devices were donated by Medtronic as part of the National Institutes ...